Drug Type Trispecific T-cell engager (TriTE) |
Synonyms- |
Target |
Action stimulants, antagonists |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CDH17 antagonists(Cadherin-17 antagonists), CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | United States | 30 Apr 2025 |